Recent Advances

New information about targeted therapies and cancer are being discovered every day. Please see the information below to learn more about the recent advances in targeted therapies and cancer genomics.
Lartruvo Gets Accelerated Approval by FDA for Sarcoma treatment
Reversal of Crizotinib Resistance
FDA approves crizotinib (Xalkori) for certain NSCLC patients
Exciting Ceritinib study results for ALK-rearranged non-small cell lung cancer (NSCLC) patients who have become resistant to treatment with crizotinib
Breakthrough Therapy Designation Granted to BI 1482694 for the Treatment of Patients with EGFR-mutated NSCLC
U.S. Food and Drug Administration (FDA) grants accelerated approval to Alecensa (alectinib)
U.S. Food and Drug Administration grants accelerated approval to Osimertinib for Non-Small Cell Lung Cancer (NSCLC) Treatment
U.S. Food and Drug Administration (FDA) approved Iressa (gefitinib)
Crizotinib treatment effective against ROS1-positive lung cancer
U. S. Food and Drug Administration granted accelerated approval to ceritinib
Mutated IDH1 identifies brain tumors that benefit from aggressive surgery
Multi-institutional team finds targetable BRAF mutations in rare brain tumor
U. S. Food and Drug Administration granted accelerated approval to trametinib and dabrafenib
U. S. Food and Drug Administration approved afatinib
MGH-led crizotinib studies shed new light on targeted lung cancer therapy
U. S. Food and Drug Administration approved dabrafenib
U. S. Food and Drug Administration approved trametinib
U. S. Food and Drug Administration approved erlotinib
Next-generation PI3 Kinase Inhibitor Demonstrated Early Efficacy, Safety
U. S. Food and Drug Administration approved regorafenib
BRAF inhibitor treatment causes melanoma cells to shift how they produce energy
Transition in cell type parallels treatment response, disease progression in breast cancer
MGH-led study of dabrafenib and trametinib named among Clinical Research Forum's Top 10 Clinical Research Achievements of 2012
Cancer Center team identifies potential treatment target for KRAS
Combination of targeted drugs delays resistance in melanoma patients
Mass. General study defines a new genetic subtype of lung cancer
Novel gene mutations associated with bile duct cancer
The path to personalized treatment
New lung cancer pill highlights improved way of treating patients
First credible treatment option for metastatic melanoma

How can we help?

Contact the Cancer Center to learn more about the testing and treatment options at Mass General.
  • Call 617-726-0808

How do I get tested?

Getting tested in one of the first steps in learning what targeted therapy may work for you. 

Learn more about how to get tested.